Ventilation With ASV Mode in Children
Launched by UNIVERSITY OF LAUSANNE HOSPITALS · Apr 25, 2019
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
The objective of the study is to assess the feasibility of ASV in children and compare physiologic values on ASV mode to Pressure-Control and Pressure-Support mode of ventilation regarding the participant is on active or passive ventilation phase.
Physiologic values will be monitored on different modes of ventilation in a randomized order. Each participant will be his own control regarding the different modes of ventilation. Monitoring will be done during 90 minutes for each mode of ventilation.
Participant will have two different phases of ventilation. The first one is the passive phase ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • children on invasive mechanical ventilation admitted in the Pediatric Intensive Care Unit at Lausanne University Hospital
- • Body weight \> 6kg
- • Absence of pulmonary comorbidity
- • Age \< 10 years
- Exclusion Criteria:
- • Patient already included in other interventional clinical study
- • body weight \< 6kg
- • age \> 10 years
- • more than 20% of air leak around endotracheal tube
- • chronic or acute pulmonary disease (ARDS, cystic fibrosis, severe asthma, lobectomy, severe bronchomalacia or severe tracheomalacia)
- • severe pulmonary hypertension on inhaled nitric oxide treatment
- • severe hemodynamic instability (more than 0.5mcg/kg/min of norepinephrine infusion or other high dose vasoactive agent infusion)
- • intracranial hypertension (more than 20mmHg if measured) or suspected intracranial hypertension
About University Of Lausanne Hospitals
The University of Lausanne Hospitals (CHUV) is a leading academic medical center in Switzerland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, CHUV focuses on translating scientific discoveries into effective treatments, fostering collaboration between researchers, healthcare professionals, and industry partners. With state-of-the-art facilities and a multidisciplinary approach, CHUV is dedicated to enhancing patient outcomes and contributing to the global body of medical knowledge through rigorous clinical trials across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, , Switzerland
Patients applied
Trial Officials
Thomas Ferry, MD
Principal Investigator
University of Lausanne Hospitals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials